Peptisource

PNC-27 30mg

PNC-27 is a chimeric p53 penetrating peptide consisting of a structural domain (residues 12-26) in the p53 protein that binds to HDM-2 and a transmembrane penetrating peptide sequence. It forms a transmembrane pore by binding to HDM-2 protein in cancer cell membranes, leading to membrane lysis and necrosis of cancer cells, while being non-toxic to normal cells. This selective mechanism has led to significant anticancer activity in a variety of cancer cells (e.g., breast cancer, pancreatic cancer, acute myeloid leukemia, etc.). PNC-27 is unique in that its mechanism of action does not depend on the functional state of p53, which makes it potentially advantageous for the treatment of tumors that are refractory to conventional p53-dependent therapies. In addition, PNC-27 has shown synergistic effects with chemotherapeutic agents such as paclitaxel, further enhancing its therapeutic potential.

Spec: 30mg
Packaging: 1kits（10Vials）
$500USD
1

▎PNC 27 Overview


PNC-27 is a chimeric p53 penetrating peptide consisting of a structural domain (residues 12-26) in the p53 protein that binds to HDM-2 and a transmembrane penetrating peptide sequence. It forms a transmembrane pore by binding to HDM-2 protein in cancer cell membranes, leading to membrane lysis and necrosis of cancer cells, while being non-toxic to normal cells. This selective mechanism has led to significant anticancer activity in a variety of cancer cells (e.g., breast cancer, pancreatic cancer, acute myeloid leukemia, etc.). PNC-27 is unique in that its mechanism of action does not depend on the functional state of p53, which makes it potentially advantageous for the treatment of tumors that are refractory to conventional p53-dependent therapies. In addition, PNC-27 has shown synergistic effects with chemotherapeutic agents such as paclitaxel, further enhancing its therapeutic potential.